Bristol-Myers Squibb
Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMY
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.
BMY Key Statistics
Stock Snapshot
Bristol-Myers Squibb(BMY) stock is priced at $57.00, giving the company a market capitalization of 116.43B. It carries a P/E multiple of 16.00 and pays a dividend yield of 4.4%.
During the trading session on 2026-05-17, Bristol-Myers Squibb(BMY) shares reached a daily high of $57.11 and a low of $56.14. At a current price of $57.00, the stock is +1.5% higher than the low and still -0.2% under the high.
Trading activity shows a volume of 10.82M, compared to an average daily volume of 9.58M.
The stock's 52-week range extends from a low of $42.52 to a high of $62.89.
The stock's 52-week range extends from a low of $42.52 to a high of $62.89.
BMY News
...
Bristol Myers Squibb (NYSE:BMY) announced a global collaboration and licensing deal with Hengrui Pharma valued at up to $15.2 billion. The agreement covers joi...
Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter,...
Analyst ratings
58%
of 31 ratingsMore BMY News
Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter,...
Advertisement Why Bristol-Myers Squibb (BMY) is on investors’ radar Bristol-Myers Squibb (BMY) has drawn fresh attention after recent trading left the stock d...
Bristol-Myers Squibb Co. (NYSE:BMY) on Tuesday announced a partnership with Hengrui Pharma to develop a portfolio of 13 early-stage programs spanning oncology,...
Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals. Dado Ruvic / Reuters U.S. phar...
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Bristol-Myers Squibb (BMY) shares fell for seven straight sessions, as the stock was down 0.9% at $55.64 on Monday. The New Jersey-based pharma giant fell 3.5%...
